Authors: | Saltz, L.; Easley, C.; Kirkpatrick, P. |
Article Title: | Panitumumab |
Abstract: | In September 2006, panitumumab (Vectibix; Amgen), a fully human antibody against the epidermal growth factor receptor (EGFR), was approved by the FDA for the treatment of patients with EGFR-expressing metastatic colorectal cancer with disease progression on or following fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. |
Keywords: | cancer survival; clinical trial; bevacizumab; erlotinib; fluorouracil; cancer combination chemotherapy; cancer growth; drug efficacy; drug safety; monotherapy; nonhuman; antineoplastic agents; drug approval; colorectal cancer; cancer immunotherapy; metastasis; lung non small cell cancer; receptor, epidermal growth factor; antineoplastic activity; food and drug administration; cetuximab; irinotecan; panitumumab; drug hypersensitivity; colorectal neoplasms; antibodies, monoclonal; add on therapy; folinic acid; neoplasm metastasis; colon carcinoma; oxaliplatin; rectum carcinoma; fluoropyrimidine; drug indication; vectibix |
Journal Title: | Nature Reviews Drug Discovery |
Volume: | 5 |
Issue: | 12 |
ISSN: | 1474-1776 |
Publisher: | Nature Publishing Group |
Date Published: | 2006-12-01 |
Start Page: | 987 |
End Page: | 988 |
Language: | English |
DOI: | 10.1038/nrd2204 |
PUBMED: | 17201026 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 20" - "Export Date: 4 June 2012" - "CODEN: NRDDA" - "Source: Scopus" |